Please login to the form below

Not currently logged in
Email:
Password:

Dr Ian Smith appointed CEO of Glide Pharma

Founder of Meridica and former Glaxo and Pfizer research executive will lead UK speciality pharma company

Dr Ian Smith - Glide Pharma, CEOUK speciality pharma firm Glide Pharma has appointed a new CEO, picking Dr Ian Smith, the former founder of the Pfizer-acquired drug delivery company Meridica.

Dr Smith, who also served as head of inhalation and device product development groups at both Glaxo and Pfizer, will take over from James Otter who had served as Glide's CEO since September, 2010 and remain as a member of the board of directors.

The company focuses on the development of solid dose formulations of therapeutics and vaccines to be used with its needle-free solid dose injector technology.

Gaining his PhD in 1972, Smith has spent the past 30 years in the pharma industry, with his most recent role as founder and director of industry consultancy firm H12 Consulting.

From November 2004 to April 2010, he was head of inhalation and devices centre of emphasis at Pfizer R&D, with global responsibility for inhaled product developments.

He held a similar role at Glaxo from November 1983 until July 1995, serving as head of inhalation product development and pharmaceutical technology.

In 2001, Dr Smith also set up and served as CEO of drug delivery firm Meridica. The company, which focused on inhaler device development, was acquired by Pfizer in 2004, with a valuation of $140m.

Commenting on his appointment, Dr Smith said: “Having spent many years in the industry, I have keenly observed the progress of Glide's unique solid dose needle-free technology, and I now look forward to playing a key role in accelerating its advance towards commercialisation.”

11th January 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics